Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CLYM

Climb Bio

CLYM Rare disease Lead: Phase 2 8 Biotech Distilled articles ↓ 42 filings & releases ↓ Cash $39.7M (Sep 30, 2026) ↓ 8 verdicts ↓ 4 timing quotes ↓
HematologyImmunologyRenal ProteinSmall Molecule

Market cap $604M 58.7M shares (10-Q, Oct 30, 2026) × $10.29 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Pipeline (8 active programs)

Capital (as filed)

Cash
$39.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$166M Sep 30, 2026
Long-term investments
$22.2M Sep 30, 2026
Operating cash flow
−$12.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$228M cash, runway 2H 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Climb Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-23 Watch Climb Bio (CLYM) - Scientific Deep Dive for Budoprutug and Pipeline Products Intriguing antibody engineering with early biological validation, but a leaky patent moat, active IP litigation, and late-to-market position make this a clinical data trade rather than a buy-and-hold investment.
  2. 2026-04-29 Speculative buy speculative UPDATE: Climb Bio (CLYM) - The Smart Money Doubles Down A $110M at-market PIPE led by a roster of healthcare-specialist funds (RA Capital, Adage, Cormorant, Redmile, et al.) provides a meaningful Bayesian update on the molecule's diligence and closes the dilution gap well past H2 2026 data readouts.
  3. 2026-05-06 Buy core UPDATE: Climb Bio (CLYM) - The SC Wedge Lands SC budoprutug matches IV at ~80% B-cell depletion in healthy volunteers, proving the commercial wedge is real, while the catalyst calendar compressed to a June ITP readout six weeks out.
  4. 2026-06-05 Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Clears Its First Bar CLYM116 cleared safety through 320 mg in 49 healthy volunteers with zero SAEs/DLTs, removing the most binary failure mode for the novel sweeper mechanism, while the June ITP patient readout remains the next key binary.
  5. 2026-06-11 Buy core UPDATE: Climb Bio (CLYM) - The ITP Bar Clears Budoprutug delivered >90% B-cell depletion and +111K platelet rise at 24 weeks in heavily pretreated ITP patients, with 3 of 4 rituximab-failures responding, providing independent clinical validation of the CD19-over-CD20 thesis.
  6. 2026-08-07 Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Gets a Date CLYM116 PK/PD reveal pinned to September 3, Mabworks deal deepened at unchanged economics, and a dense Q4 catalyst cluster is fully funded; holding through the catalyst cluster remains defensible while trimming into the +28% run is also noted as reasonable.
  7. 2026-09-03 Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Delivers Its Number CLYM116 posted a ~29-day half-life (~3x sibeprenlimab) with >90% free APRIL suppression and 60-75% IgA knockdown through 12 weeks off a single dose, converting the dosing-frequency wedge from modeled to measured; PrisMN replication remains the Q4 lead-asset valuation event.
  8. 2026-10-27 Hold UPDATE: Climb Bio (CLYM) - The Leaky Sieve PrisMN 200 mg cohort showed incomplete B-cell depletion (74% vs. 100% in Phase 1b) due to 2x faster drug clearance in proteinuric patients, deferring complete-remission data to 2027 just as obinutuzumab nears approval; mechanism is intact but the right dose is undecided and the lead-asset payoff is delayed.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (42)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)